| Project Title | Length of Follow-up Time for New Users of Immunosuppressive Drugs |
| Date Posted | Wednesday, February 28, 2018 |
| Project ID | cder_mpl1p_wp006_nsdp_v01 |
| Status | Complete |
| Deliverables | |
| Description | This report contains estimates of the length of follow-up time for new users of immunosuppressive drugs (adalimumab, alemtuzumab, certolizumab, dalfampridine, dimethyl fumarate, etanercept, fingolimod, glatiramer acetate, golimumab, infliximab, interferon beta-1A, interferon beta-1B, mitoxantrone, natalizumab, pegylated intereferon beta-1A, teriflunomide, and ustekinumab) and for patients diagnosed with Crohn's disease, multiple sclerosis, psoriasis, and ulcerative colitis in the Sentinel Distributed Database (SDD). This report was distributed to Data Partners on June 30, 2017. |
| Medical Product | adalimumab alemtuzumab certolizumab dalfampridine dimethyl fumarate etanercept fingolimod glatiramer acetate golimumab infliximab interferon beta-1A interferon beta-1B mitoxantrone natalizumab pegylated interferon beta-1A teriflunomide ustekinumab |
| Population / Cohort | Individuals 18 years of age or older |
| Time Period | January 1, 2000 - June 30, 2017 |
| Assessment Type | Exploratory Analyses |
| Study Type | Modular Program |
| Data Sources | Sentinel Distributed Database (SDD) |
| FDA Center | CDER |
